Ladies and Gentlemen,

The European Forum on Oncology will be held for the first time on the 28th and 29th of October 2010 in the Hotel Concorde Berlin. The goal of the Forum is to highlight and discuss excellent research and healthcare projects in Europe in order to strengthen European cancer research and health care delivery in the area of oncology.

Cancer is the leading cause of death in Europe after heart disease. Nonetheless, the conditions for cancer treatment and the quality of early detection, diagnosis and therapy still vary considerably within the European Union. This is what the EUROPEAN FORUM ON ONCOLOGY 2010 will address. Leaders in the German and European healthcare sector will meet in Berlin in October 2010 in order to find a common approach, discuss the most promising concepts in cancer therapy and to further improve the quality of research and oncology treatment throughout Europe. Experts in medicine, science and health care policy will discuss how research in Europe can be organized in a more viable and cost effective manner and how the findings of medical research can be translated more quickly into effective treatment strategies.

Organisations such as the European Society for Medical Oncology (ESMO), Société Française du Cancer (SFC), Joint Working Group of the Scientific Medical Societies in Germany (AWMF), the Organisation of European Cancer Institutes (OECI) and the European Hospital and Healthcare Federation (HOPE) are supporting the EUROPEAN FORUM ON ONCOLOGY.

It would be a pleasure for me to meet you in Berlin on the 28th and 29th of October 2010 at the European Forum on Oncology.

Sincerely,

Peter M. Schlag
Professor of Surgical Oncology, Charité – Medical School Berlin
Director Charité Comprehensive Cancer Center
Scientific Advisor to the European Forum on Oncology

Program Overview

Thursday, 28th October 2010

9.00 - 10.00 h. Registration and Distribution of Conference Documents
10.00 - 11.00 h. Welcoming Remarks
11.00 - 12.30 h. Podium Discussion
12.30 - 13.30 h. Symposium 1
13.30 - 14.30 h. Symposium 2
14.30 - 15.30 h. Symposium 3
15.30 - 16.30 h. Symposium 4
16.00 - 17.00 h. Coffee Break
17.00 - 18.30 h. Get-together

Friday, 29th October 2010

9.00 - 10.30 h. Symposium 5
10.30 - 11.30 h. Symposium 6
11.30 - 13.00 h. Coffee Break
13.00 - 14.00 h. Symposium 7
14.00 - 15.15 h. Forum 1
15.15 - 16.00 h. Forum 2
16.00 - 17.00 h. Forum 3
17.00 - 18.00 h. Forum 4
18.00 - 18.45 h. Forum 5
18.45 - 20.00 h. Forum 6
20.00 - 21.30 h. Get-together

P. Schlag
Professor of Surgical Oncology, Charité – Medical School Berlin
Director Charité Comprehensive Cancer Center
Scientific Advisor to the European Forum on Oncology
Program Thursday, 28th October 2010

9.00 h.
Registration and Distribution of Conference Documents

10.00 h.
Welcoming Remarks
Ulf Fink, Senator a.D.
Congress President

Status Report:
Cancer in Europe and the World – Challenges and Outlook
Prof. Dr. Peter Boyle
President, International Prevention Research Institute, Lyon, France

Status Report:
Challenges for Cancer Research and Cancer Medicine
Prof. Dr. Otmar D. Wiestler
Chairman of the Board, German Cancer Research Center DKFZ, Heidelberg

11.00 h.
Podium Discussion
Oncology in the Healthcare Policy Arena
Introduction and Moderation:
Prof. Dr. Michael Bamberg
Chief Medical Officer, University Clinic for Radiooncology, University Hospital Tuebingen

Jan-Willem van de Loo, Ph.D.
Head, Department of Cancer Research, Medical and Public Health Research, Directorate-General for Research, European Commission, Brussels, Belgium

Karin Knufmann-Happe
Head, Department of Prevention, Health Safety, Disease Control and Biomedicine, Federal Ministry of Health, Berlin

Dr. Bernhard Egger
Head, Department of Medicine, Central Association of Statutory Health Insurers, Berlin

12.30 h. to 13.30 h. Lunch

13.30 h. to 14.30 h.
Symposium 1
Prospects of Cancer Diagnosis
Introduction and Moderation:
Prof. Dr. Dr. Alfred Holzgreve
Director, Clinical Research and Academic Instruction, Vivantes Network for Health GmbH, Berlin

Molecular Imaging – An Overview
Prof. Hartmut Kolb, Ph.D.
Vice President, Siemens MI Biomarker Research, Culver City, USA

Oncology and Modern Analysis of Metabolism – The First Data from the Representative Study SHIP
Prof. Dr. Matthias Nauck
Director, Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Greifswald

Tumor Pathology – Current Status and Prospects
Prof. Dr. Manfred Dietel
Director, Institute of Pathology, Charité – Medical School Berlin

Subsequently: Discussion

14.30 h. to 15.30 h.
Symposium 2
Prospects of Oncological Surgery and Interventional Procedures
Introduction and Moderation:
Prof. Dr. Hartwig Bauer
General Secretary, German Society of Surgeons, Berlin

Status of Oncological Surgery – Germany and the EU
Prof. Dr. Cornelis van de Velde
President, European Society of Surgical Oncology (ESSO), Brussels, Belgium

Prospects of Tumor Surgery
Prof. Dr. Serge Evrard
President, Société Française du Cancer (SFC) and General Secretary, Société Française de Chirurgie Oncologique (SFCO), Bordeaux, France

Interventional Oncology Therapy Procedures
Prof. Dr. Thomas J. Vogl
Director, Institute of Diagnostical and Interventional Radiology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main

Endoscopic Cancer Therapies
Prof. Dr. Alexander Meining
Head, Endoscopy, II. Medical Clinic, Klinikum rechts der Isar, Technical University Munich

Subsequently: Discussion

15.30 h. to 16.00 h. Coffee Break

16.00 h. to 17.00 h.
Symposium 3
Prospects of Radiooncology
Introduction and Moderation:
Prof. Dr. Volker Budach
Director, Clinic of Radiation Therapy at the Charité, Charité – Medical School Berlin

Further Development of Standard Radiation Therapy
Prof. Dr. Michael Baumann
Director, Clinic for Radiation Therapy and Radiooncology, OncoRay – Center for Innovation Competence, University Hospital Dresden and President, European Cancer Organisation (ECCO), Brussels, Belgium
Particle Therapy
Prof. Dr. Dr. Jürgen Debus
Chief Medical Officer, Clinic for RadioOncology
Radiation Therapy, University Hospital Heidelberg

Nuclear Medicine
Prof. Dr. Wim Oyen
Head, Department of Nuclear Medicine,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands

Results of the TARGETed Intra operative Radiotherapy Study (TARGIT-Study)
Prof. Dr. Frederik Wenz
Director, Clinic for Radiation Therapy and Radiooncology, University Hospital Mannheim

Subsequently: Discussion

17.00 h. to 18.30 h.
Symposium 4
Prospects of Haematology – Oncology and Drug Therapy
Introduction and Moderation:
Prof. Dr. Thomas Tursz
General Director, Institut Gustave Roussy,
Villejuif, France

Current Status of Targeted Medicine
Prof. Dr. Michael Thomas, M.D.
Chief Medical Officer, Department of Oncology/Internal Medicine, Thorax Clinic,
University Hospital Heidelberg

Subsequently: Discussion

Drug Therapy for Solid Tumors – quo vadis
Prof. Dr. Jürgen Wolf
Chief Medical Officer, Center for Integrated Oncology,
Clinic I for Internal Medicine, University Hospital Cologne

Immune Therapy for Cancer
Prof. Dr. Cornelis J M Melief
Department of Immune Haematology, Leiden
University Medical Center, Leiden, The Netherlands

Paediatric Oncology
Prof. Dr. Dr. Günter Henze
Director, Clinic Paediatrics with Focus on Oncology and Haematology, Charité – Medical School Berlin

Subsequently: Discussion

18.30 h.
Get-together

Program Friday, 29th October 2010

9.00 h. to 10.30 h.
Symposium 5
Targeted Oncology
Introduction and Moderation:
Dr. Tobias Eichhorn
General Manager Oncology Germany,
Pfizer Pharma GmbH, Berlin

Overview:
System Biology and Oncology
Prof. Olaf Wolkenhauer, PhD
Head, Department of Systems Biology and Bioinformatics, Rostock University

Pharmacogenetics
Prof. Dr. Jos Beijnen
Head, Department of Pharmacy & Pharmacology,
Member of the Board of Management, Slotervaart Hospital and National Cancer Institute Amsterdam,
The Netherlands

Structural Conceptions for the Implementation of a Targeted Oncology with Patient Participation: Case Study from a Leading Oncological Center
Prof. Dr. Dr. h.c. Peter M. Schlag
Professor of Surgical Oncology,
Charité – Medical School Berlin, Director Charité Comprehensive Cancer Center, Scientific Advisor to the European Forum on Oncology

Subsequently: Discussion

10.30 h. to 11.00 h. Coffee Break

11.00 h. to 13.00 h.
Symposium 6
European Partnership for Measures to Control Cancer 2009 - 2013 – Current Status and Prospects of the Coordination in the EU
Introduction and Moderation:
Dr. Karen Budewig
Federal Ministry of Health, Berlin
**Program Friday, 29th October 2010**

### Introduction and Overview: Areas of Action for the EU-Partnership

**Mojca Gruntar Činč, M.D.**
Coordinator, European Partnership for Measures to Combat Cancer and Director General for Public Health, Ministry of Health, Ljubljana, Slovenia

*Impulse Presentations on selected Areas of Action for the EU-Partnership:*

#### Health Protection

**Dr. Josep M. Borràs**
Director, Catalan Cancer Strategy, Department of Health Barcelona and Scientific Coordinator, Spanish Strategy on Cancer, Institut Català de Oncologia, Ministry of Health and Social Policy, Madrid, Spain

#### Research

**Prof. Dr. Michael Baumann**
Director, Clinic for Radiation Therapy and Radiooncology, OncoRay – Center for Innovation Competence, University Hospital Dresden and President, European Cancer Organisation (ECCO), Brussels, Belgium

#### Healthcare Information and Statistics

**Dr. Milena Sant**
Department of Preventative and Predictive Medicine, Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

#### Harmonization of National Cancer Plans with the EU-Initiative on Combating Cancer

**Sandra Radoš Krnel**
Coordinator, Steering Group/National Cancer Plans, Institute of Public Health, Ljubljana, Slovenia

### 13.00 h. to 14.00 h. Lunch

### 14.00 h. to 15.15 h. **Forums 1-3**

#### Forum 1

**Cost-Benefit-Analysis of Oncological Innovations in selected EU-Countries**

*Introduction and Moderation:*

**Prof. Dr. Bertram Häussler**
Chairman of the Board of Management, IGES Institut GmbH, Berlin

*Impulse Presentations:*

**Prof. Dr. Thomas Tursz**
General Director, Institut Gustave Roussy, Villejuif, France

**Prof. Dr. Christopher Twelves**
Vice Director, Clinical Cancer Research, UK Clinical Centre, St. James's University Hospital, Leeds, United Kingdom

**Prof. Dr. Axel Heyll**
Head, Competence Center Oncology at the Medical Services Agency of the Statutory Health Insurers, Dusseldorf

**Prof. Dr. Wim van Harten**
Designated President, Organisation of European Cancer Institutes (OECI), The Netherlands Cancer Institute, Amsterdam, The Netherlands

#### Forum 2

**Breast Cancer**

*Introduction and Moderation:*

**Prof. Dr. Dr. Manfred Kaufmann**
Director, Clinic for Gynaecology and Obstetrics, Johann Wolfgang Goethe University Hospital, Frankfurt am Main

*Overview Presentation: Breast Cancer – Treatment in the EU*

**Dr. Claudia Allemani**
Department of Preventative and Predictive Medicine, Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

*Conclusion: How do we curtail the differences in outcomes in the EU?*

**Prof. Dr. Hans-Jörg Senn**
Chairman, St. Gallen Oncology Conferences, Tumor- and Breast Center ZeTuP, St. Gallen, Switzerland

*Subsequently: Discussion*

#### Forum 3

**Vaccinations against Cancer – Current Status and Prospects**

*Introduction and Moderation:*

**Prof. Dr. Norbert Suttorp**
Director, Medical Clinic with Focus Infectiology and Pneumology, Charité – Medical School Berlin

*Overview Presentation: What is in the Pipeline?*

**Prof. Dr. Lutz Gissmann**
Head, Department of Infection and Cancer, Gene-Modification and Carcinogenesis, German Cancer Research Center, Heidelberg

*Subsequently: Discussion*
**Forum 4**

**Cancer in an Ageing Society**

*Introduction and Moderation:*
Dr. Ulrich Wedding
Head, Department of Palliative Medicine, Clinic for Internal Medicine II, University Hospital Jena

**Trends and Clinical Challenges**
Prof. Dr. Ernst Späth-Schwalbe, MBA
Head Physician, Department of Hematology, Oncology, Gastroenterology, Palliative Medicine, Vivantes Hospital Spandau, Berlin

**Solutions and Aspects for the Future**
Prof. Dr. Hans Wildiers
Department of General Medical Oncology, University Leuven, Leuven, Belgium

*Subsequently: Discussion*

---

**Forum 5**

**Prostate Cancer**

*Introduction and Moderation:*
Prof. Dr. Hartwig Huland
Chief Medical Officer, Martini-Klinik am UKE GmbH, Hamburg

**Overview Presentation: Prostate Cancer – Differences in Treatment, Management and Outcomes in the EU**
Prof. Dr. Jan Adolfsson
Director, Oncology Center, Karolinska Institutet, Stockholm, Sweden

**European Randomised Study on Screenings for Prostate Cancer: Current Status and Clinical Applications**
Dr. Monique Roobol
Study Coordinator, Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands

*Subsequently: Discussion*

---

**Forum 6**

**Cancer Research in Europe – Current Status and Prospects**

*Introduction and Moderation:*
Dr. Marco Pierotti
President, Organisation of European Cancer Institutes (OECI) and Director, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

**Excellence in Cancer Research in the EU and its implementation**
Prof. Dr. Ulrik Ringborg
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

---

**Health Services Research in Oncology**
Dr. Dirk Holler
Pricing & Market Access Director, AstraZeneca, Macclesfield, United Kingdom

**Industrial Research in Oncology**
Dr. Michael Warmbold
Vice President, Medical Europe, Pfizer Pharma GmbH, Berlin

*Subsequently: Discussion*

---

16.45 h. to 17.00 h.

**Ratification of Berlin Memorandum: Perspectives on Cancer Therapy in Europe**

17.00 h.
Get-together
| Speakers |
|-----------------|-----------------|-----------------|-----------------|
| **Prof. Dr. Jan Adolfsson**  
Director, Oncology Center, Karolinska Institutet, Stockholm, Sweden | **Dr. Karen Budewig**  
Federal Ministry of Health, Berlin | **Prof. Dr. Lutz Gissmann**  
Head, Department of Infection and Cancer, Gene-Modification and Carcinogenesis, German Cancer Research Center, Heidelberg |
| **Dr. Claudia Allemani**  
Department of Preventative and Predictive Medicine, Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy | **Prof. Dr. Antoine Carpentier**  
Department of Neurology, Hôpital de la Salpêtrière, Paris, France | **Mojca Gruntar Činč, M.D.**  
Coordinator, European Partnership for Measures to Combat Cancer and Director General for Public Health, Ministry of Health, Ljubljana, Slovenia |
| **Prof. Dr. Michael Bamberg**  
Chief Medical Officer, University Clinic for Radiooncology, University Hospital Tuebingen | **Prof. Dr. Dr. Jürgen Debus**  
Chief Medical Officer and Clinic for RadioOncology Radiation Therapy, University Hospital Heidelberg | **Prof. Dr. Wim van Harten**  
Designated President, Organisation of European Cancer Institutes (OECI), The Netherlands Cancer Institute, Amsterdam, The Netherlands |
| **Prof. Dr. Hartwig Bauer**  
General Secretary, German Society of Surgeons, Berlin | **Prof. Dr. Manfred Dietel**  
Director, Institute of Pathology, Charité – Medical School Berlin | **Prof. Dr. Bertram Häussler**  
Chairman of the Board of Management, IGES Institut GmbH, Berlin |
| **Prof. Dr. Michael Baumann**  
Director, Clinic for Radiation Therapy and Radiooncology, OncoRay – Center for Innovation Competence, University Hospital Dresden and President, European Cancer Organisation (ECCO), Brussels, Belgium | **Dr. Bernhard Egger**  
Head, Department of Medicine, Central Association of Statutory Health Insurers, Berlin | **Prof. Dr. Dr. Günter Henze**  
Director, Clinic Paediatrics with Focus on Oncology and Haemotology, Charité – Medical School Berlin |
| **Prof. Dr. Jos Beijnen**  
Head, Department of Pharmacy & Pharmacology, Member of the Board of Management, Slotervaart Hospital, National Cancer Institute Amsterdam, The Netherlands | **Dr. Tobias Eichhorn**  
General Manager, Oncology Germany, Pfizer Pharma GmbH, Berlin | **Dr. Dirk Holler**  
Pricing & Market Access Director, AstraZeneca, Macclesfield, United Kingdom |
| **Prof. Dr. Peter Boyle**  
President, International Prevention Research Institute, Lyon, France | **Prof. Dr. Serge Evrard**  
President, Société Française du Cancer (SFC) and General Secretary, Société Française de Chirurgie Oncologique (SFCO), Bordeaux, France | **Prof. Dr. Dr. Alfred Holzgreve**  
Director, Clinical Research and Academic Instruction, Vivantes Network for Health GmbH, Berlin |
| **Prof. Dr. Volker Budach**  
Director, Clinic of Radiation Therapy at the Charité, Charité – Medical School Berlin | **Ulf Fink, Senator a.D.**  
Congress President, Founder and Shareholder of the WISO-Group, Chairmann, Health City Berlin | **Prof. Dr. Hartwig Huland**  
Chief Medical Officer, Martini-Klinik am UKE GmbH, Hamburg |
Speakers

Prof. Dr. Dr. Manfred Kaufmann  
Director, Clinic for Gynaecology and Obstetrics, Johann Wolfgang Goethe University Hospital, Frankfurt am Main

Karin Knufmann-Happe  
Head, Department of Prevention, Health Safety, Disease Control and Biomedicine, Federal Ministry of Health, Berlin

Prof. Hartmuth Kolb, Ph.D.  
Vice President, Siemens MI Biomarker Research, Culver City, USA

Jan-Willem van de Loo, Ph.D.  
Head, Department of Cancer Research, Medical and Public Health Research, Directorate-General for Research, European Commission, Brussels, Belgium

Prof. Dr. Alexander Meining  
Head, Endoscopy, II. Medical Clinic, Klinikum rechts der Isar, Technical University Munich

Prof. Dr. Cornelis J M Melief  
Department of Immune Haematology, Leiden University Medical Center, Leiden, The Netherlands

Prof. Dr. Matthias Nauck  
Director, Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Greifswald

Prof. Dr. Wim Oyen  
Head, Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Prof. Dr. Giorgio Parmiani  
Head, Department of Immuno-Biotherapy for Melanoma and Solid Tumors, San Raffaele Foundation, Scientific Institute, Milan, Italy

Dr. Marco Pierotti  
President, Organisation of European Cancer Institutes (OECI) and Director, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Sandra Radoš Krnel  
Coordinator, Steering Group/National Cancer Plans, Institute of Public Health, Ljubljana, Slovenia

Prof. Dr. Ulrik Ringborg  
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

Dr. Monique Roobol  
Study Coordinator, Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands

Dr. Milena Sant  
Department of Preventative and Predictive Medicine, Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Prof. Dr. Dr. h.c. Peter M. Schlag  
Professor for Surgical Oncology, Charité – Medical School Berlin, Director Charité Comprehensive Cancer Center, Scientific Advisor to the European Forum on Oncology

Prof. Dr. Ernst Späth-Schwalbe, MBA  
Head Physician, Department of Haematology, Oncology, Gastroenterology, Palliative Medicine, Vivantes Hospital Spandau, Berlin

Prof. Dr. Hans-Jörg Senn  
Chairman, St. Gallen Oncology Conferences, Tumor- and Breast Center ZeTuP, St. Gallen, Switzerland

Prof. Dr. Norbert Suttorp  
Director, Medical Clinic with Focus Infectiology and Pneumology, Charité – Medical School Berlin

Prof. Dr. Michael Thomas, M.D.  
Chief Medical Officer, Department of Oncology/Internal Medicine, Thorax Clinic, University Hospital Heidelberg

Prof. Dr. Thomas Tursz  
General Director, Institut Gustave Roussy, Villejuif, France

Prof. Dr. Christopher Twelves  
Vice Director, Clinical Cancer Research, UK Clinical Centre, St. James’s University Hospital, Leeds, United Kingdom

Prof. Dr. Cornelis van de Velde  
President, European Society of Surgical Oncology (ESSO), Brussels, Belgium

Prof. Dr. Thomas J. Vogl  
Director, Institute of Diagnostical and Interventional Radiology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main

Dr. Michael Warmbold  
Vice President, Medical Europe, Pfizer Pharma GmbH, Berlin
Speakers

Dr. Ulrich Wedding
Head, Department of Palliative Medicine,
Clinic for Internal Medicine II,
University Hospital Jena

Prof. Dr. Frederik Wenz
Director, Clinic for Radiation
Therapy and Radiooncology,
University Hospital Mannheim

Prof. Dr. Otmar D. Wiestler
Chairman of the Board, German Cancer
Research Center DKFZ, Heidelberg

Prof. Dr. Hans Wildiers
Department of General Medical Oncology,
University Leuven, Belgium

Prof. Dr. Jürgen Wolf
Chief Medical Officer, Center for Integrated
Oncology, Clinic I for Internal Medicine,
University Hospital Cologne

Prof. Olaf Wolkenhauer, PhD
Head, Department of Systems Biology and
BioInformatics, Rostock University

Further speakers:

Dr. Josep M. Borràs
Director, Catalan Cancer Strategy, Department of Health
Barcelona and Scientific Coordinator, Spanish Strategy on
Cancer, Instituto Catalan de Oncologia, Ministry of Health
and Social Policy, Madrid, Spain

Prof. Dr. Axel Heyll
Head, Competence Center Oncology at the Medical Services
Agency of the Statutory Health Insurers, Dusseldorf

The EUROPEAN FORUM ON ONCOLOGY 2010 is supported by:

PARTNERS

AstraZeneca

Boehringer Ingelheim

Merck Serono

MERCK

Pfizer

SIEMENS

COOPERATING PROFESSIONAL SOCIETIES

ESMO

OEIC

HOPE

AWMF

Berliner Krebsgesellschaft e.V.

Hotel Concorde Berlin
Augusburger Str. 41, 10789 Berlin

AIRPORT
Tegel 20 min
Schoenefeld 30 min

RAILWAY
Hauptbahnhof 10 min

BY CAR
From A100/A115 take exit "Kurfuerstendamm/
Zentrum". After 4 km on
Kurfuerstendamm, turn right
into Rankestraße and then
right into Augusburger Straße.
Registration to the **EUROPEAN FORUM ON ONCOLOGY 2010**

**Payment**
Following registration, you will be sent an invoice. A limited number of rooms are available in the Hotel Concorde Berlin for attendees, key words: „Forum Onkologie“.

**Continued Education for Doctors**
The **EUROPEAN FORUM ON ONCOLOGY 2010** has been certified by the Berlin Medical Association to qualify as Continued Education.

**Cancellation**
This registration is binding but can be transferred to comparable parties at any time. Cancellations must be submitted in writing to the Congress Office. A cancellation fee of 60.00 EUR incl. 19% VAT will be charged. No refunds will be provided for cancellations received after 30 September 2010.

**Kindly register via facsimile +49 30 70011 7604, with a window envelope or online under www.forum-onkologie.eu**

**I** register with binding effect as an employee of a hospital at the hospital fee of 490.00 EUR (583.10 EUR incl. 19% VAT).
**I** register with binding effect at the standard rate of 860.00 EUR (1,023.40 EUR incl. 19% VAT).

**Ms.**  **Mr.**

**Title**

**First Name**

**Family Name**

**Function / Field of Service**

**Name of Cooperating Professional Society**

**Name of Research Institute**

**Institution**

- Hospital
- Management / Administration
- Association / Journalism
- Research / Scientific
- Industry / Business
- Other:
- Private Practice
- Insurance

**Billing Address**

**Institution / Company**

**Department**

**Street, Number**

**Postal Code, City**

**Telephone**  **Telefax**

**E-Mail**

**Date, Signature**
Location
Hotel Concorde Berlin
Augsburger Str. 41
10789 Berlin
FON  +49 30 800 999 0
FAX  +49 30 800 999 99

Congress Office
EUROPEAN FORUM ON ONCOLOGY 2010
Französische Str. 23
10117 Berlin
FON  +49 30 70011 7615
FAX  +49 30 70011 7604
kongress@forum-onkologie.eu
www.forum-onkologie.eu

Coordination
Gesundheitsstadt Berlin GmbH
Dr. Franz Dormann
General Manager
www.gesundheitsstadt-berlin.de

Organizer
WISO S. E. Consulting GmbH
Dr. Ingrid Völker
Managing Partner
Claudia Küng
General Manager
www.wiso-gruppe.de